Bluebird BIo shares are trading higher after Barclays upgraded the stock from Equal-Weight to Overweight and raised its price target from $7 to $8.
Portfolio Pulse from Benzinga Newsdesk
Barclays upgraded Bluebird Bio's stock from Equal-Weight to Overweight and raised its price target from $7 to $8, resulting in higher trading for the company's shares.
June 01, 2023 | 1:17 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Bluebird Bio's stock upgraded by Barclays to Overweight with a raised price target of $8, leading to higher trading.
The upgrade from Barclays to Overweight and the raised price target from $7 to $8 indicate a positive outlook for Bluebird Bio's stock. This news is likely to attract more investors, driving the stock price higher in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100